NEW YORK, July 28, 2021 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors from. Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA). These investors are advised to contact Robert S. Willoughby To [email protected] or 888-476-6529, ext. 7980.
The purpose of the investigation is to determine whether Athira and any of its officers and / or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On or around September 18, 2021, Athira proceeded to its initial public offering (“IPO”) by selling 12 million shares at a price of $ 17.00 per share. Then on June 17, 2021, Athira announced that the Company’s Board of Directors has appointed its President and CEO, Leen kawas, on temporary leave pending an investigation into “actions arising from doctoral research conducted by Dr. Kawas while he was at Washington State University. ”
On this news, Athira’s share price fell $ 7.09 per share, or 38.87%, to close at $ 11.15 per share on June 18, 2021.
The Pomerantz firm, with offices in new York, Chicago, Los Angeles, and Paris is recognized as one of the leading firms in the areas of corporate law, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz was a pioneer in the field of class actions in securities. Today, more than 80 years later, Pomerantz continues the tradition it established, fighting for the rights of victims of securities fraud, breach of fiduciary duty and professional misconduct. The firm has recovered numerous multi-million dollar damages on behalf of the members of the group. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext 7980
SOURCE Pomerantz LLP